PF573228 in combination with erlotinib reduced cell viability and tumor growth in EGFR TKI-resistant non-small cell lung cancer (NSCLC) more effective than treatment with erlotinib alone in the A549 mouse xenograft model57. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.